Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder

Gary Sachs, Charles Bowden, Joseph R. Calabrese, Terence Ketter, Thomas Thompson, Robin White, Beth Bentley

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Objective: The effect of lamotrigine maintenance therapy on body weight was assessed retrospectively in analyses of data from two double-blind, placebo- and lithium-controlled, 18-month studies in patients with bipolar I disorder (n = 227 for lamotrigine, 190 for placebo, 166 for lithium). Methods: Endpoints included mean change in weight, the percentage of patients with ≥7% change (increase, decrease, fluctuation) in weight, and the percentage of patients with weight-related adverse events during double-blind treatment. Results: Mean weight remained stable during maintenance therapy with lamotrigine. In a mixed-model repeated-measures analysis, mean changes in weight (kg) at week 52 were -1.2 with lamotrigine, +0.2 with placebo, and +2.2 with lithium [estimated difference (95% CI) lamotrigine minus placebo = -1.3 (-3.6, 0.9), p = 0.237; lithium minus placebo = +2.0 (-0.3, 4.4), p = 0.094; lithium minus lamotrigine = +3.4 (1.4, 5.4), p < 0.001]. Analyses were truncated at week 52 because of the high incidence of missing data at later time points. The percentages of patients with a ≥7% weight gain, during randomized treatment, were 10.9%, 7.6% and 11.8% for the lamotrigine, placebo, and lithium groups, respectively. The percentages of patients with a ≥7% weight loss, during randomized treatment, were 12.1%, 11.5%, and 5.1% for the lamotrigine, placebo, and lithium groups, respectively. The percentage of patients with a ≥7% weight loss did not significantly differ between lamotrigine and placebo but was significantly higher with lamotrigine than lithium. The incidences of ≥7% weight changes and of weight changes reported as adverse events were comparable between active treatments and placebo. Conclusion: Lamotrigine was associated with stable body weight during 1 year of treatment and was comparable to placebo in mean weight change, incidence of clinically significant weight change, and incidence of weight changes reported as adverse events in patients with bipolar disorder. Lithium was associated with weight gain, but the magnitude of lithium-associated weight gain was lower in the current analysis than in previous studies.

Original languageEnglish (US)
Pages (from-to)175-181
Number of pages7
JournalBipolar Disorders
Volume8
Issue number2
DOIs
StatePublished - Apr 2006

Fingerprint

Bipolar Disorder
Lithium
Placebos
Weights and Measures
Therapeutics
Weight Gain
Incidence
Weight Loss
Body Weight Maintenance
lamotrigine
Body Weight

Keywords

  • Bipolar disorder
  • Lamotrigine
  • Lithium
  • Maintenance therapy
  • Weight

ASJC Scopus subject areas

  • Neuroscience(all)
  • Neuropsychology and Physiological Psychology

Cite this

Sachs, G., Bowden, C., Calabrese, J. R., Ketter, T., Thompson, T., White, R., & Bentley, B. (2006). Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disorders, 8(2), 175-181. https://doi.org/10.1111/j.1399-5618.2006.00308.x

Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. / Sachs, Gary; Bowden, Charles; Calabrese, Joseph R.; Ketter, Terence; Thompson, Thomas; White, Robin; Bentley, Beth.

In: Bipolar Disorders, Vol. 8, No. 2, 04.2006, p. 175-181.

Research output: Contribution to journalArticle

Sachs, G, Bowden, C, Calabrese, JR, Ketter, T, Thompson, T, White, R & Bentley, B 2006, 'Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder', Bipolar Disorders, vol. 8, no. 2, pp. 175-181. https://doi.org/10.1111/j.1399-5618.2006.00308.x
Sachs, Gary ; Bowden, Charles ; Calabrese, Joseph R. ; Ketter, Terence ; Thompson, Thomas ; White, Robin ; Bentley, Beth. / Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. In: Bipolar Disorders. 2006 ; Vol. 8, No. 2. pp. 175-181.
@article{342d925f3aba431bb2d7c3045a062770,
title = "Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder",
abstract = "Objective: The effect of lamotrigine maintenance therapy on body weight was assessed retrospectively in analyses of data from two double-blind, placebo- and lithium-controlled, 18-month studies in patients with bipolar I disorder (n = 227 for lamotrigine, 190 for placebo, 166 for lithium). Methods: Endpoints included mean change in weight, the percentage of patients with ≥7{\%} change (increase, decrease, fluctuation) in weight, and the percentage of patients with weight-related adverse events during double-blind treatment. Results: Mean weight remained stable during maintenance therapy with lamotrigine. In a mixed-model repeated-measures analysis, mean changes in weight (kg) at week 52 were -1.2 with lamotrigine, +0.2 with placebo, and +2.2 with lithium [estimated difference (95{\%} CI) lamotrigine minus placebo = -1.3 (-3.6, 0.9), p = 0.237; lithium minus placebo = +2.0 (-0.3, 4.4), p = 0.094; lithium minus lamotrigine = +3.4 (1.4, 5.4), p < 0.001]. Analyses were truncated at week 52 because of the high incidence of missing data at later time points. The percentages of patients with a ≥7{\%} weight gain, during randomized treatment, were 10.9{\%}, 7.6{\%} and 11.8{\%} for the lamotrigine, placebo, and lithium groups, respectively. The percentages of patients with a ≥7{\%} weight loss, during randomized treatment, were 12.1{\%}, 11.5{\%}, and 5.1{\%} for the lamotrigine, placebo, and lithium groups, respectively. The percentage of patients with a ≥7{\%} weight loss did not significantly differ between lamotrigine and placebo but was significantly higher with lamotrigine than lithium. The incidences of ≥7{\%} weight changes and of weight changes reported as adverse events were comparable between active treatments and placebo. Conclusion: Lamotrigine was associated with stable body weight during 1 year of treatment and was comparable to placebo in mean weight change, incidence of clinically significant weight change, and incidence of weight changes reported as adverse events in patients with bipolar disorder. Lithium was associated with weight gain, but the magnitude of lithium-associated weight gain was lower in the current analysis than in previous studies.",
keywords = "Bipolar disorder, Lamotrigine, Lithium, Maintenance therapy, Weight",
author = "Gary Sachs and Charles Bowden and Calabrese, {Joseph R.} and Terence Ketter and Thomas Thompson and Robin White and Beth Bentley",
year = "2006",
month = "4",
doi = "10.1111/j.1399-5618.2006.00308.x",
language = "English (US)",
volume = "8",
pages = "175--181",
journal = "Bipolar Disorders",
issn = "1398-5647",
publisher = "Blackwell Munksgaard",
number = "2",

}

TY - JOUR

T1 - Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder

AU - Sachs, Gary

AU - Bowden, Charles

AU - Calabrese, Joseph R.

AU - Ketter, Terence

AU - Thompson, Thomas

AU - White, Robin

AU - Bentley, Beth

PY - 2006/4

Y1 - 2006/4

N2 - Objective: The effect of lamotrigine maintenance therapy on body weight was assessed retrospectively in analyses of data from two double-blind, placebo- and lithium-controlled, 18-month studies in patients with bipolar I disorder (n = 227 for lamotrigine, 190 for placebo, 166 for lithium). Methods: Endpoints included mean change in weight, the percentage of patients with ≥7% change (increase, decrease, fluctuation) in weight, and the percentage of patients with weight-related adverse events during double-blind treatment. Results: Mean weight remained stable during maintenance therapy with lamotrigine. In a mixed-model repeated-measures analysis, mean changes in weight (kg) at week 52 were -1.2 with lamotrigine, +0.2 with placebo, and +2.2 with lithium [estimated difference (95% CI) lamotrigine minus placebo = -1.3 (-3.6, 0.9), p = 0.237; lithium minus placebo = +2.0 (-0.3, 4.4), p = 0.094; lithium minus lamotrigine = +3.4 (1.4, 5.4), p < 0.001]. Analyses were truncated at week 52 because of the high incidence of missing data at later time points. The percentages of patients with a ≥7% weight gain, during randomized treatment, were 10.9%, 7.6% and 11.8% for the lamotrigine, placebo, and lithium groups, respectively. The percentages of patients with a ≥7% weight loss, during randomized treatment, were 12.1%, 11.5%, and 5.1% for the lamotrigine, placebo, and lithium groups, respectively. The percentage of patients with a ≥7% weight loss did not significantly differ between lamotrigine and placebo but was significantly higher with lamotrigine than lithium. The incidences of ≥7% weight changes and of weight changes reported as adverse events were comparable between active treatments and placebo. Conclusion: Lamotrigine was associated with stable body weight during 1 year of treatment and was comparable to placebo in mean weight change, incidence of clinically significant weight change, and incidence of weight changes reported as adverse events in patients with bipolar disorder. Lithium was associated with weight gain, but the magnitude of lithium-associated weight gain was lower in the current analysis than in previous studies.

AB - Objective: The effect of lamotrigine maintenance therapy on body weight was assessed retrospectively in analyses of data from two double-blind, placebo- and lithium-controlled, 18-month studies in patients with bipolar I disorder (n = 227 for lamotrigine, 190 for placebo, 166 for lithium). Methods: Endpoints included mean change in weight, the percentage of patients with ≥7% change (increase, decrease, fluctuation) in weight, and the percentage of patients with weight-related adverse events during double-blind treatment. Results: Mean weight remained stable during maintenance therapy with lamotrigine. In a mixed-model repeated-measures analysis, mean changes in weight (kg) at week 52 were -1.2 with lamotrigine, +0.2 with placebo, and +2.2 with lithium [estimated difference (95% CI) lamotrigine minus placebo = -1.3 (-3.6, 0.9), p = 0.237; lithium minus placebo = +2.0 (-0.3, 4.4), p = 0.094; lithium minus lamotrigine = +3.4 (1.4, 5.4), p < 0.001]. Analyses were truncated at week 52 because of the high incidence of missing data at later time points. The percentages of patients with a ≥7% weight gain, during randomized treatment, were 10.9%, 7.6% and 11.8% for the lamotrigine, placebo, and lithium groups, respectively. The percentages of patients with a ≥7% weight loss, during randomized treatment, were 12.1%, 11.5%, and 5.1% for the lamotrigine, placebo, and lithium groups, respectively. The percentage of patients with a ≥7% weight loss did not significantly differ between lamotrigine and placebo but was significantly higher with lamotrigine than lithium. The incidences of ≥7% weight changes and of weight changes reported as adverse events were comparable between active treatments and placebo. Conclusion: Lamotrigine was associated with stable body weight during 1 year of treatment and was comparable to placebo in mean weight change, incidence of clinically significant weight change, and incidence of weight changes reported as adverse events in patients with bipolar disorder. Lithium was associated with weight gain, but the magnitude of lithium-associated weight gain was lower in the current analysis than in previous studies.

KW - Bipolar disorder

KW - Lamotrigine

KW - Lithium

KW - Maintenance therapy

KW - Weight

UR - http://www.scopus.com/inward/record.url?scp=33745835789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745835789&partnerID=8YFLogxK

U2 - 10.1111/j.1399-5618.2006.00308.x

DO - 10.1111/j.1399-5618.2006.00308.x

M3 - Article

VL - 8

SP - 175

EP - 181

JO - Bipolar Disorders

JF - Bipolar Disorders

SN - 1398-5647

IS - 2

ER -